151 related articles for article (PubMed ID: 31378709)
21. Proof of concept for poor inhibitor binding and efficient formation of covalent adducts of KRAS
Khrenova MG; Kulakova AM; Nemukhin AV
Org Biomol Chem; 2020 Apr; 18(16):3069-3081. PubMed ID: 32101243
[TBL] [Abstract][Full Text] [Related]
22. Kinetic analysis by fluorescence of the interaction between Ras and the catalytic domain of the guanine nucleotide exchange factor Cdc25Mm.
Lenzen C; Cool RH; Prinz H; Kuhlmann J; Wittinghofer A
Biochemistry; 1998 May; 37(20):7420-30. PubMed ID: 9585556
[TBL] [Abstract][Full Text] [Related]
23. Ras activation revisited: role of GEF and GAP systems.
Hennig A; Markwart R; Esparza-Franco MA; Ladds G; Rubio I
Biol Chem; 2015 Aug; 396(8):831-48. PubMed ID: 25781681
[TBL] [Abstract][Full Text] [Related]
24. Specific biochemical inactivation of oncogenic Ras proteins by nucleoside diphosphate kinase.
Fischbach MA; Settleman J
Cancer Res; 2003 Jul; 63(14):4089-94. PubMed ID: 12874011
[TBL] [Abstract][Full Text] [Related]
25. High-frequency 94 GHz ENDOR characterization of the metal binding site in wild-type Ras x GDP and its oncogenic mutant G12V in frozen solution.
Bennati M; Hertel MM; Fritscher J; Prisner TF; Weiden N; Hofweber R; Spörner M; Horn G; Kalbitzer HR
Biochemistry; 2006 Jan; 45(1):42-50. PubMed ID: 16388579
[TBL] [Abstract][Full Text] [Related]
26. Drugging all RAS isoforms with one pocket.
Kessler D; Bergner A; Böttcher J; Fischer G; Döbel S; Hinkel M; Müllauer B; Weiss-Puxbaum A; McConnell DB
Future Med Chem; 2020 Nov; 12(21):1911-1923. PubMed ID: 32779487
[TBL] [Abstract][Full Text] [Related]
27. Crystal structures of Ral-GppNHp and Ral-GDP reveal two binding sites that are also present in Ras and Rap.
Nicely NI; Kosak J; de Serrano V; Mattos C
Structure; 2004 Nov; 12(11):2025-36. PubMed ID: 15530367
[TBL] [Abstract][Full Text] [Related]
28. What makes Ras an efficient molecular switch: a computational, biophysical, and structural study of Ras-GDP interactions with mutants of Raf.
Filchtinski D; Sharabi O; Rüppel A; Vetter IR; Herrmann C; Shifman JM
J Mol Biol; 2010 Jun; 399(3):422-35. PubMed ID: 20361980
[TBL] [Abstract][Full Text] [Related]
29. NMR
Sharma AK; Lee SJ; Rigby AC; Townson SA
Biomol NMR Assign; 2018 Oct; 12(2):269-272. PubMed ID: 29721757
[TBL] [Abstract][Full Text] [Related]
30. Assays for Nucleotide Competitive Reversible and Irreversible Inhibitors of Ras GTPases.
Jeganathan S; Müller MP; Ali I; Goody RS
Biochemistry; 2018 Aug; 57(31):4690-4699. PubMed ID: 29791793
[TBL] [Abstract][Full Text] [Related]
31. High-Throughput Dual Screening Method for Ras Activities and Inhibitors.
Kopra K; van Adrichem AJ; Salo-Ahen OMH; Peltonen J; Wennerberg K; Härmä H
Anal Chem; 2017 Apr; 89(8):4508-4516. PubMed ID: 28318223
[TBL] [Abstract][Full Text] [Related]
32. Nucleotide based covalent inhibitors of KRas can only be efficient in vivo if they bind reversibly with GTP-like affinity.
Müller MP; Jeganathan S; Heidrich A; Campos J; Goody RS
Sci Rep; 2017 Jun; 7(1):3687. PubMed ID: 28623374
[TBL] [Abstract][Full Text] [Related]
33. The structural basis for the transition from Ras-GTP to Ras-GDP.
Hall BE; Bar-Sagi D; Nassar N
Proc Natl Acad Sci U S A; 2002 Sep; 99(19):12138-42. PubMed ID: 12213964
[TBL] [Abstract][Full Text] [Related]
34. Guanosine triphosphatase stimulation of oncogenic Ras mutants.
Ahmadian MR; Zor T; Vogt D; Kabsch W; Selinger Z; Wittinghofer A; Scheffzek K
Proc Natl Acad Sci U S A; 1999 Jun; 96(12):7065-70. PubMed ID: 10359839
[TBL] [Abstract][Full Text] [Related]
35. Ras-guanine nucleotide complexes: A UV spectral deconvolution method to analyze protein concentration, nucleotide stoichiometry, and purity.
Swisher GH; Hannan JP; Cordaro NJ; Erbse AH; Falke JJ
Anal Biochem; 2021 Apr; 618():114066. PubMed ID: 33485819
[TBL] [Abstract][Full Text] [Related]
36. Real-time monitoring of the reaction of KRAS G12C mutant specific covalent inhibitor by in vitro and in-cell NMR spectroscopy.
Zhao Q; Haga R; Tamura S; Shimada I; Nishida N
Sci Rep; 2023 Nov; 13(1):19253. PubMed ID: 37935773
[TBL] [Abstract][Full Text] [Related]
37. Characterisation of the nucleotide exchange factor ITSN1L: evidence for a kinetic discrimination of GEF-stimulated nucleotide release from Cdc42.
Kintscher C; Groemping Y
J Mol Biol; 2009 Mar; 387(2):270-83. PubMed ID: 19356586
[TBL] [Abstract][Full Text] [Related]
38. Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C.
Zeng M; Lu J; Li L; Feru F; Quan C; Gero TW; Ficarro SB; Xiong Y; Ambrogio C; Paranal RM; Catalano M; Shao J; Wong KK; Marto JA; Fischer ES; Jänne PA; Scott DA; Westover KD; Gray NS
Cell Chem Biol; 2017 Aug; 24(8):1005-1016.e3. PubMed ID: 28781124
[TBL] [Abstract][Full Text] [Related]
39. NMR
Sharma AK; Lee SJ; Zhou M; Rigby AC; Townson SA
Biomol NMR Assign; 2019 Apr; 13(1):227-231. PubMed ID: 30798456
[TBL] [Abstract][Full Text] [Related]
40. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
Janes MR; Zhang J; Li LS; Hansen R; Peters U; Guo X; Chen Y; Babbar A; Firdaus SJ; Darjania L; Feng J; Chen JH; Li S; Li S; Long YO; Thach C; Liu Y; Zarieh A; Ely T; Kucharski JM; Kessler LV; Wu T; Yu K; Wang Y; Yao Y; Deng X; Zarrinkar PP; Brehmer D; Dhanak D; Lorenzi MV; Hu-Lowe D; Patricelli MP; Ren P; Liu Y
Cell; 2018 Jan; 172(3):578-589.e17. PubMed ID: 29373830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
